Gedatolisib + Palbociclib + Fulvestrant
HR+/HER2- Advanced Breast Cancer (PIK3CA Wild-Type)
Key Facts
Indication
HR+/HER2- Advanced Breast Cancer (PIK3CA Wild-Type)
Phase
Phase 3
Status
Active
Company
About Celcuity
Celcuity is a clinical-stage biotech focused on developing targeted therapies for cancers driven by the PAM pathway. Its strategic pivot from diagnostics to therapeutics is centered on the late-stage development of gedatolisib, a highly differentiated dual inhibitor. Recent Phase 3 data in HR+/HER2- advanced breast cancer suggests practice-changing potential, positioning the company for a pivotal transition to commercialization if successful.
View full company profile